KALV Fail-to-Deliver

KalVista Pharmaceuticals, Inc. (KALV) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.44B, listed on NASDAQ, employing roughly 275 people, carrying a beta of -0.29 to the broader market. KalVista Pharmaceuticals, Inc. Led by Benjamin L. Palleiko, public since 2015-04-09.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date

2026-06-15

Latest FTD Quantity

13

Latest Price

$27.00

30-Day Avg FTD

44.8K

30-Day Total FTD

1.3M

Showing 30 days of SEC fail-to-deliver data for KalVista Pharmaceuticals, Inc..

Learn how fails-to-deliver is reported and how to read the data →